Astellas Pharma Inc
F:YPHA

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
F:YPHA
Watchlist
Price: 11.2 EUR -0.88% Market Closed
Market Cap: 20B EUR

Astellas Pharma Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Astellas Pharma Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Operating Income
ÂĄ145.8B
CAGR 3-Years
-14%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Income
ÂĄ373.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Operating Income
ÂĄ289.3B
CAGR 3-Years
51%
CAGR 5-Years
21%
CAGR 10-Years
11%
Otsuka Holdings Co Ltd
TSE:4578
Operating Income
ÂĄ457.6B
CAGR 3-Years
48%
CAGR 5-Years
16%
CAGR 10-Years
8%
S
Shionogi & Co Ltd
TSE:4507
Operating Income
ÂĄ155.5B
CAGR 3-Years
17%
CAGR 5-Years
4%
CAGR 10-Years
10%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Income
ÂĄ553.2B
CAGR 3-Years
-12%
CAGR 5-Years
15%
CAGR 10-Years
21%
No Stocks Found

Astellas Pharma Inc
Glance View

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

YPHA Intrinsic Value
10.19 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Operating Income?
Operating Income
145.8B JPY

Based on the financial report for Sep 30, 2025, Astellas Pharma Inc's Operating Income amounts to 145.8B JPY.

What is Astellas Pharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-4%

Over the last year, the Operating Income growth was 21%. The average annual Operating Income growth rates for Astellas Pharma Inc have been -14% over the past three years , -3% over the past five years , and -4% over the past ten years .

Back to Top